<DOC>
	<DOCNO>NCT00559455</DOCNO>
	<brief_summary>Primary objective : To determine Tumor Response Rate patient hepatocellular carcinoma treat combination chemotherapy Eloxatin+5-FU/LV Secondary objective : To evaluate time progression , 6month survival , overall survival , safety tolerability patient hepatocellular carcinoma treat combination chemotherapy Eloxatin+5-FU/LV</brief_summary>
	<brief_title>Phase II Study Eloxatin+5-FU/LV Patients With Unresectable Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Lists Inclusion Exclusion criterion : Patients must histologically confirm hepatocellular carcinoma Patients must measurable disease CT scan Have receive previous palliative systemic chemotherapy metastatic disease . ( Adjuvant chemotherapy radiation therapy non target lesion allow . ) Patients progress previous local treatment time randomization least 4 week last interventional therapy ( Hepatic Artery Infusion , TransArtery Embolization TransArtery ChemoEmbolization ) least 4 week last radiotherapy/ablation/ Percutaneous Ethanol Injection target lesion . WHO 02 grade ( Karnofsky Performance Score ≥ 70 ) Patients must adequate organ marrow function : Neutrophilus ≥ 1.5 x 10^9/L Platelets ≥ 75 x 10^9/L Asparagine AminoTransferase , Alanine AminoTransferase &lt; 2.5 x Upper Normal Limit ( UNL ) Total Bilirubin ≤ 1.5 x UNL International Normalized Ratio &lt; 1.5 Child stage A B Creatinine ≤ 1.5 X UNL Documented allergy platinum compound study drug . Active GastroIntestinal bleed active haematologic malignancy Previous liver transplantation . Patients concomitantly receive anticancer therapy . Patients receive study treatment . Pregnant lactate woman woman childbearing potential without proper contraceptive method . History malignant disease , except cure basal cell carcinoma skin cure carcinoma insitu uterine cervix . Central nervous system metastasis Other serious illness medical condition Neuropathy ≥ grade 2 The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>